Department of Surgery and Anaesthesiology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium.
Department of Surgery and Anaesthesiology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium.
Vet J. 2021 Apr;270:105626. doi: 10.1016/j.tvjl.2021.105626. Epub 2021 Feb 1.
An established lipopolysaccharide (LPS) model previously described in Warmbloods, was inconsistent in Standardbred horses, where lameness was not detected despite the presence of synovitis. The present study aimed to determine the dose of LPS from E. coli O55:B5 required to induce mild to moderate lameness following middle carpal joint injection in Standardbred horses and to quantitate the induced lameness over time, with and without anti-inflammatory pre-treatment. In a baseline trial, eight healthy, clinically sound Standardbred horses were used in a rule-based dose-escalation design trial, starting at a dose of 10 endotoxin units (EU). Lameness at trot was evaluated visually and quantitatively (using an inertial-sensor system and pressure plate analysis). Synovial fluid aspirates were analysed for total nucleated cell counts, total protein and prostaglandin E (PGE). Following 2 months wash-out, the effective LPS-dose determined in the baseline trial was used to evaluate the effect of anti-inflammatory treatment. A mixed model for repeated measures with horse as random effect was used for analysis. After injection of 10 EU LPS, the desired degree of lameness was observed in the baseline trial, with maximal lameness at post-injection hour (PIH) 4, followed by a rapid decline and return to baseline by PIH 48. No lameness was observed following pre-treatment with meloxicam. In synovial fluid, PGE was significantly higher at PIH 8 and PIH 24 in the baseline trial compared with following meloxicam pre-treatment. In conclusion, injection of the middle carpal joint with 10 EU LPS consistently induces a transient lameness and synovitis in Standardbred horses.
先前在温血马中描述的一种已建立的脂多糖（LPS）模型在纯血马中并不一致，尽管存在滑膜炎，但没有检测到跛行。本研究旨在确定大肠杆菌 O55:B5 的 LPS 剂量，以便在标准bred 马的腕中关节注射后引起轻度至中度跛行，并随着时间的推移定量评估跛行，同时使用和不使用抗炎预处理。在基线试验中，使用基于规则的剂量递增设计试验，使用 8 匹健康、临床状况良好的标准bred 马，起始剂量为 10 个内毒素单位（EU）。通过视觉和定量（使用惯性传感器系统和压力板分析）评估跑步时的跛行。分析滑液抽吸物的总核细胞计数、总蛋白和前列腺素 E（PGE）。经过 2 个月的洗脱期，在基线试验中确定有效的 LPS 剂量，用于评估抗炎治疗的效果。使用混合模型进行重复测量，马作为随机效应进行分析。在注射 10 EU LPS 后，在基线试验中观察到所需程度的跛行，最大跛行发生在注射后小时（PIH）4，随后迅速下降并在 PIH 48 时恢复到基线。在使用美洛昔康预处理后，没有观察到跛行。在滑膜液中，与美洛昔康预处理后相比，在基线试验中 PIH 8 和 PIH 24 时 PGE 显著升高。总之，腕中关节注射 10 EU LPS 可在标准bred 马中持续引起短暂的跛行和滑膜炎。
